Many diseases of the nervous system are accompanied by alterations in synaptic functions.
Synaptic plasticity mediated by the endogenous cannabinoid system involves the activation …

Arachidonoylglycerol (2-AG) is the most abundant endogenous cannabinoid in the brain
and an agonist at two cannabinoid receptors (CB 1 and CB 2). The synthesis, degradation …

The study of endocannabinoid pharmacology has proceeded from the discovery of Δ9-
tetrahydrocannabinol, the main psychoactive compound in Cannabis sativa, to the …

There is growing interest in using cannabinoid receptor 2 (CB2) agonists for the treatment of
neuropathic pain and other indications. In continuation of our ongoing program aiming for …

It is now clear that, in contrast to traditional descriptions of G protein-coupled receptor
signaling, agonists can activate or inhibit characteristic patterns of downstream effector …

Introduction In the last two decades, our understanding of the therapeutic utility and
medicinal properties of cannabis has greatly changed. This change has been accompanied …

Background and Purpose Cannabinoid (CB) ligands have been demonstrated to have utility
as novel therapeutic agents for the treatment of pain, metabolic conditions and …

Although the first studies regarding the endogenous opioid system and addiction were
published during the 1940s, addiction and cannabinoids were not addressed until the …

Abstract Cannabinoid receptor 1 (CB1R), a G protein‐coupled receptor, plays a fundamental
role in synaptic plasticity. Abnormal activity and deregulation of CB1R signaling result in a …

One of the most abundant G-protein coupled receptors (GPCRs) in brain, the cannabinoid 1
receptor (CB1R), is a tractable therapeutic target for treating diverse psychobehavioral and …